TCL Archive Gleevec Maintenance Therapy Showed Significant Benefits At Three Years in Phase III Trial April 27, 2012
TCL Archive Healy Transfers $15 Million From NCI to Fund Cancer Research Around NIH; Another $16M Held January 24, 1992
TCL Archive New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years October 26, 2012